Chart Events
Performance Outlook
| Previous Close | 103.00 |
| Open | 103.00 |
| Bid | 0.00 x 30000 |
| Ask | 0.00 x 30000 |
| Day's Range | 102.00 - 105.00 |
| 52 Week Range | 59.50 - 136.00 |
| Volume | 48 |
| Avg. Volume | 154 |
| Market Cap | 11.616B |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | 15.70 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.23 (0.23%) |
| Ex-Dividend Date | Apr 15, 2021 |
| 1y Target Est | N/A |
Fair Value
Related Research
- Zacks
Why Is PerkinElmer (PKI) Down 9.6% Since Last Earnings Report?
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Moody's
PerkinElmer, Inc. -- Moody's assigns Baa3 rating to PerkinElmer's notes offering
Rating Action: Moody's assigns Baa3 rating to PerkinElmer's notes offeringGlobal Credit Research - 04 Mar 2021New York, March 04, 2021 -- Moody's Investors Service, ("Moody's") assigned a Baa3 rating to the proposed offering of senior unsecured 10- and 30-year notes of PerkinElmer, Inc. ("PerkinElmer"). There are no changes to Moody's existing ratings of PerkinElmer including the Baa3 senior unsecured long-term rating. The acquisition slightly increases PerkinElmer's financial leverage to close to 3.0x, up from 2.5x in the last twelve months to September 30, 2020.
- Zacks
Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio
Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.
